Efficacy of potassium-competitive acid blocker (P-CAB)- based therapeutic regimens in the eradication of resistant Helicobacter pylori strains

Authors

Keywords:

Anti-Bacterial agents, Drug therapy Combination, Helicobacter pylori, Retrospective studies, Treatment Outcome

Abstract

Helicobacter pylori infection is a severe public health issue, characterized by high prevalence in Latin America and a strong association with the development of gastric cancer. Given the growing bacterial resistance to conventional therapy based on proton pump inhibitors (PPIs), potassium-competitive acid blockers (P-CABs) emerge as a promising alternative. The present study aims to evaluate the efficacy of P-CABs, focusing on vonoprazan and tegoprazan, in the eradication of resistant H. pylori strains compared to PPIs. To this end, a literature review was conducted in the PubMed/MEDLINE, Embase, Cochrane, and Web of Science databases, encompassing publications particularly from the last 10 years. The results indicate that P-CABs promote faster, more potent, and sustained acid suppression without being subjected to interference from CYP2C19 polymorphisms. Vonoprazan-based regimens achieve overall eradication rates of 86% to 94%, outperforming PPIs, especially in clarithromycin-resistant strains (66% to 81% efficacy against 32% to 40% for PPIs). Highdose vonoprazan dual therapy stood out for its high efficacy and lower incidence of adverse events. Thus, it is concluded that P-CABs represent a significant therapeutic advance, offering greater reliability in combating antimicrobial resistance. However, due to the scarcity of robust data on Latin American populations, future regional clinical trials and cost-effectiveness evaluations tailored to the reality of the Brazilian healthcare system become essential to substantiate new clinical guidelines.

References

Kanu JE, Soldera J. Treatment of Helicobacter Pylori With Potassium Competitive Acid Blockers: A Systematic Review and Meta-Analysis. World J Gastroenterol [Internet]. Mar 2024 [Citado em 1 Mai 2026]; 30(9): 1213-23. Disponível em: https://pubmed.ncbi.nlm.nih.gov/38577188/. doi: 10.3748/wjg.v30.i9.1213.

Almadi MA, Lu Y, Alali AA, Barkun AN. Peptic Ulcer Disease. Lancet [Internet]. Ago 2024 [Citado em 1 Mai 2026]; 404(10447): 68-81. Disponível em: https://pubmed.ncbi.nlm.nih. gov/38885678/. doi: 10.1016/S0140-6736(24)00155-7.

Coelho LG, Coelho MC. Clinical Management of Helicobacter Pylori: The Latin American Perspective. Dig Dis [Internet]. 2014 [Citado em 1 Mai 2026]; 32(3): 302-9. Disponível em: https://pubmed.ncbi.nlm.nih.gov/24732197/. doi: 10.1159/000360615.

GLOBOCAN / Global Cancer Observatory (Dados atualizados sobre a América Latina e o Caribe, 2022-2024) [Internet]. Lyon: International Agency for Research on Cancer; 2024 [Citado em 1 Mai 2026]. Disponível em: https://gco.iarc.who.int/.

Fallone CA, Moss SF, Malfertheiner P. Reconciliation of Recent Helicobacter Pylori Treatment Guidelines in a Time of Increasing Resistance to Antibiotics. Gastroenterology [Internet]. Jul 2019 [Citado em 1 Mai 2026]; 157(1): 44-53. Disponível em: https://pubmed.ncbi.nlm.nih.gov/30998990/. doi: 10.1053/j.gastro.2019.04.011.

Schulz C, Liou JM, Alboraie M, Bornschein J, Campos Nunez C, Coelho LG, Quach DT, Fallone CA, Chen YC, Gerhard M, Gisbert JP, Jung HY, Katelaris PH, Kim JG, Lu H, Macke L, Mahachai V, Moss SF, Remes Troche JM, Riquelme A, Romano M, Setshedi M, Smith S, Suerbaum S, Tshibangu-Kabamba E, Vilaichone RK, Yadegar A, Yamaoka Y, Mégraud F, El-Omar EM, Sugano K, Malfertheiner P. Helicobacter pylori antibiotic resistance: a global challenge in search of solutions. Gut [Internet]. 2025 [Citado em 1 Mai 2026]; : gutjnl-2025-335523. Disponível em: https://pubmed.ncbi.nlm.nih.gov/40645767/. doi: 10.1136/gutjnl-2025-335523.

Contreras M, Mujica H, García-Amado MA. Molecular tools of antibiotic resistance for Helicobacter pylori: an overview in Latin America. Front Gastroenterol (Lausanne) [Internet]. Jul 2024 [Citado em 1 Mai 2026]; 3: 1410816. Disponível em: https://pubmed.ncbi.nlm.nih.gov/41822721/. doi: 10.3389/fgstr.2024.1410816.

Patel A, Laine L, Moayyedi P, Wu J. AGA Clinical Practice Update on Integrating Potassium-Competitive Acid Blockers Into Clinical Practice: Expert Review. Gastroenterology [Internet]. 2024 [Citado em 1 Mai 2026]; 167(6): 1228-38. Disponível em: https://linkinghub.elsevier.com/retrieve/pii/S0016-5085(24)05226-0. doi: 10.1053/j.gastro.2024.06.038.

Chey WD, Howden CW, Moss SF, Morgan DR, Greer KB, Grover S, Shah SC. ACG Clinical Guideline: Treatment of Helicobacter pylori Infection. Am J Gastroenterol [Internet]. 2024 [Citado em 1 Mai 2026]; 119(9): 1730-53. Disponível em: https://doi.org/10.14309/ajg.0000000000002968. doi: 10.14309/ajg.0000000000002968.

Abdel-Aziz Y, Metz DC, Howden CW. Review Article: Potassium-Competitive Acid Blockers for the Treatment of Acid-Related Disorders. Aliment Pharmacol Ther [Internet]. 2021 [Citado em 1 Mai 2026]; 53(7): 794-809. Disponível em: https://pubmed.ncbi.nlm.nih.gov/33592125/. doi: 10.1111/apt.16295.

Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book) [Internet]. Silver Spring: Food and Drug Administration; 2026 [Citado em 3 Jun 2026]. Disponível em: https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book.

Chey WD, Mégraud F, Laine L, López LJ, Hunt BJ, Howden CW. Vonoprazan Triple and Dual Therapy for Helicobacter Pylori Infection in the United States and Europe: Randomized Clinical Trial. Gastroenterology [Internet]. Set 2022 [Citado em 1 Mai 2026]; 163(3): 608-19. Disponível em: https://pubmed.ncbi.nlm.nih.gov/35679950/. doi: 10.1053/j. gastro.2022.05.055.

Takahashi N, Take Y. Tegoprazan, a Novel Potassium-Competitive Acid Blocker to Control Gastric Acid Secretion and Motility. J Pharmacol Exp Ther [Internet]. Fev 2018 [Citado em 1 Mai 2026]; 364(2): 275-86. Disponível em: https://pubmed.ncbi.nlm.nih.gov/29180359/. doi: 10.1124/jpet.117.244202.

Benito BM, Nyssen OP, Gisbert JP. Efficacy and Safety of Vonoprazan in Dual/Triple/Quadruple Regimens Both in First-Line and Rescue Therapy for Helicobacter Pylori Eradication: A Systematic Review With Meta-Analysis. Helicobacter [Internet]. Nov-Dez 2024 [Citado em 1 Mai 2026]; 29(6): e13148. Disponível em: https://pubmed.ncbi.nlm.nih. gov/39533409/. doi: 10.1111/hel.13148.

Liu L, Shi H, Shi Y, Wang A, Guo N, Li F, Nahata MC. Vonoprazan-Based Therapies Versus PPI-based Therapies in Patients With H. Pylori Infection: Systematic Review and Meta-Analyses of Randomized Controlled Trials. Helicobacter [Internet]. Mai-Jun 2024 [Citado em 1 Mai 2026]; 29(3): e13094. Disponível em: https://pubmed.ncbi.nlm.nih. gov/38790090/. doi: 10.1111/hel.13094.

Cho JH, Jin SY, Park S. Comparison of Tegoprazan and Proton Pump Inhibitors for First-Line Helicobacter Pylori Eradication: A Systematic Review With Meta-Analysis. Expert Rev Anti Infect Ther [Internet]. Fev-Abr 2025 [Citado em 1 Mai 2026]; 23(2-4): 227-33. Disponível em: https://pubmed.ncbi.nlm.nih.gov/39862182/. doi: 10.1080/14787210.2025.2459722.

Park JY, Hong SJ, Choi IJ, Baik GH, Kim SM, Park JJ, Jeon SW, Kim KO, Lee SK, Jung HY, Oh JH, Park CH, Kim SW, Shim KN, Jee SR, Moon HS, Moon JS, Choi CW, Lee WS, Kim JG. Tegoprazan-Based Triple Therapy for Helicobacter Pylori Eradication: A Phase III Multicenter Randomized Clinical Trial. Helicobacter [Internet]. Jan-Fev 2026 [Citado em 1 Mai 2026]; 31(1): e70106. Disponível em: https://pubmed.ncbi.nlm.nih.gov/41531249/. doi: 10.1111/hel.70106.

Song Z, Wang W, Li P, Zuo X, Zhu Y, Chen Y, Zhang X, Lyu B, Lin R, Du Y, Lan C, Wu H, Chen W, Ye Y, Fan H, Liao A, Chen H, Liu C, Zhang Z, Wang W, Suo Z, Li X, Du Q, Li X, Pan F, Tang J, Xu M, Liu X, Zheng P, Chen H, Du L, Lu J, Feng C, Pan W, Wang H, Zeng Z, Wang J, Lyu S, Liu D, Yang S, Li L, Zhou L. Tegoprazan-Based Versus Esomeprazole-Based Triple Therapy Plus Bismuth for First-Line Helicobacter Pylori Eradication: A Nationwide, Multicenter, Double-Blind, Double-Dummy, Randomized Controlled Trial. Chin Med J [Internet]. 2025 [Citado em 1 Mai 2026]; : 00029330-990000000-01705. Disponível em: https://pubmed.ncbi.nlm.nih.gov/40846665/. doi: 10.1097/CM9.0000000000003780.

Zhang WL, Lin BS, Li YY, Ding YM, Han ZX, Ji R. Efficacy and Safety of Vonoprazan and Amoxicillin Dual Therapy for Helicobacter Pylori Eradication: A Systematic Review and Meta- Analysis. Digestion [Internet]. 2023 [Citado em 1 Mai 2026]; 104(4): 249-61. Disponível em: https://pubmed.ncbi.nlm.nih.gov/37015201/. doi: 10.1159/000529622.

Rokkas T, Ekmektzoglou K, Niv Y, Graham DY. Comparative Efficacy and Safety of Potassium-Competitive Acid Blocker-Based Dual, Triple, and Quadruple Regimens for First-Line Helicobacter Pylori Infection Treatment: A Systematic Review and Network Meta-Analysis. Am J Gastroenterol [Internet]. 2025 [Citado em 1 Mai 2026]; 120(4): 787-98. Disponível em: https://pubmed.ncbi.nlm.nih.gov/39298553/. doi: 10.14309/ajg.0000000000003084.

Ouyang M, Zou S, Cheng Q, Shi X, Sun M. Comparative Efficacy and Safety of Potassium-Competitive Acid Blockers and Proton Pump Inhibitors for First-Line Helicobacter Pylori Eradication Therapy: A Systematic Review and Network Meta-Analysis. Helicobacter [Internet]. Nov-Dez 2024 [Citado em 1 Mai 2026]; 29(6): e13150. Disponível em: https:// pubmed.ncbi.nlm.nih.gov/39508303/. doi: 10.1111/hel.13150.

Zhang J, Zhang H, Zhu XJ, Yao N, Yin JM, Liu J, Dan HJ, Pang QM, Liu ZH, Shi YQ. Efficacy and safety of vonoprazan and high-dose amoxicillin dual therapy in eradicating Helicobacter pylori: A systematic review and meta-analysis. Int J Antimicrob Agents [Internet]. 2024 [Citado em 1 Mai 2026]; 64(5): 107331. Disponível em: https://pubmed.ncbi.nlm.nih. gov/39251094/. doi: 10.1016/j.ijantimicag.2024.107331.

Qian HS, Li WJ, Dang YN, Li LR, Xu XB, Yuan L, Zhang WF, Yang Z, Gao X, Zhang M, Li X, Zhang GX. Ten-Day Vonoprazan-Amoxicillin Dual Therapy as a First-Line Treatment of Helicobacter pylori Infection Compared With Bismuth-Containing Quadruple Therapy. Am J Gastroenterol [Internet]. 2023 [Citado em 1 Mai 2026]; 118(4): 627-34. Disponível em: https://pubmed.ncbi.nlm.nih.gov/36729890/. doi: 10.14309/ajg.0000000000002086.

Sanches BSF, Nyssen OP, Chaves SR, Veloso JS, Silva LS, Marinho JR, Okamoto H, Couto GC, Breyer HP, Alencar CS, Comelli E, Sousa LS, Horn M, Massote MG, Loures MTR, Vidal MP, Paula RV, Ribeiro LT, Galizzi HO, Terra DAA, Cançado GGL, Burmann BP, Caetano JS, Pena LF, Decanio MA, Souza HS, Kuniyoshi ASO, Guedes LR, Passos MCF, Marinho FP, Bombassaro IZ, Domingues AG, Barbosa JG, Nogueira IM, Ramos AFP, Korman DR, Souza TB, Barbosa MC, Chinzon D, Silva LL, Mantovani A, Freitas AHA, Poncinelli CS, Francato MA, Goncalves JN, Parra P, Cano-Català A, Moreira L, Gisbert JP, Coelho LGV, Hp-BrazilReg. Empirical Rescue Eradication Therapy for Helicobacter Pylori Infection in Second and Subsequent Treatment Lines: Experience From 500 Cases of the Brazilian Registry on H. Pylori Management (Hp-BrazilReg). Helicobacter [Internet]. Set-Out 2025 [Citado em 1 Mai 2026]; 30(5): e70077. Disponível em: https://pubmed.ncbi.nlm.nih.gov/41088538/. doi: 10.1111/hel.70077.

Jin T, Wu W, Zhang L, Xuan H, Zhang H, Zhong L. The efficacy and safety of Vonoprazan and Tegoprazan in Helicobacter pylori eradication: a comprehensive systematic review and meta-analysis of randomized controlled trials. Ther Adv Gastroenterol [Internet]. 2025 [Citado em 1 Mai 2026]; 18: 17562848251314801. Disponível em: https://pubmed.ncbi.nlm. nih.gov/39898357/. doi: 10.1177/17562848251314801.

Yunusa I, Love BL. Cost-Effectiveness of Vonoprazan-Based and Rifabutin-Based vs Other Regimens as First-Line Treatment of Helicobacter Pylori Infection in the United States. Am J Gastroenterol [Internet]. 2023 [Citado em 1 Mai 2026]; 118(4): 635-44. Disponível em: https://pubmed.ncbi.nlm.nih.gov/36693030/. doi: 10.14309/ajg.0000000000002146.

Scarpignato C, Hunt RH. Potassium-Competitive Acid Blockers: Current Clinical Use and Future Developments. Curr Gastroenterol Rep [Internet]. 2024 [Citado em 1 Mai 2026]; 26(11): 273-93. Disponível em: https://pubmed.ncbi.nlm.nih.gov/39145848/. doi: 10.1007/s11894-024-00939-3.

Tietto A, Faggin S, Scarpignato C, Savarino EV, Giron MC. Safety of Potassium-Competitive Acid Blockers in the Treatment of Gastroesophageal Reflux Disease. Expert Opin Drug Metab Toxicol [Internet]. 2025 [Citado em 1 Mai 2026]; 21(1): 53-68. Disponível em: https://pubmed.ncbi.nlm.nih.gov/39189409/. doi: 10.1080/17425255.2024.2397433.

Camargo MC, García A, Riquelme A, Otero W, Camargo CA, Hernandez-García T, Candia R, Bruce MG, Rabkin CS. The problem of Helicobacter pylori resistance to antibiotics: a systematic review in Latin America. Am J Gastroenterol [Internet]. Abr 2014 [Citado em 1 Mai 2026]; 109(4): 485-95. Disponível em: https://pubmed.ncbi.nlm.nih.gov/24589670/. doi: 10.1038/ajg.2014.24.

Shah SC, Tepler A, Chung CP, Suarez G, Peek RM Jr, Hung A, Roumie C, Narula N. Host Genetic Determinants Associated With Helicobacter pylori Eradication Treatment Failure: A Systematic Review and Meta-analysis. Gastroenterology [Internet]. 2021 [Citado em 1 Mai 2026]; 161(5): 1443-59. Disponível em: https://pubmed.ncbi.nlm.nih.gov/34358488/. doi: 10.1053/j.gastro.2021.07.043.

Shah SC, Iyer PG, Moss SF. AGA Clinical Practice Update on the Management of Refractory Helicobacter Pylori Infection: Expert Review. Gastroenterology [Internet]. 2021 [Citado em 1 Mai 2026]; 160(5): 1831-41. Disponível em: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8281326/. doi: 10.1053/j.gastro.2020.11.059.

Programação da XXIV Semana Brasileira do Aparelho Digestivo [Internet]. SBAD; 2025 [Citado em 3 Jun 2026]. Disponível em: https://sbad.com.br/evento/sbad2025/ programacao/lista.

Hossa K, Małecka-Wojciesko E. Advances in Gastroesophageal Reflux Disease Management: Exploring the Role of Potassium-Competitive Acid Blockers and Novel Therapies. Pharmaceuticals (Basel) [Internet]. 2025 [Citado em 1 Mai 2026]; 18(5): 699. Disponível em: https://pubmed.ncbi.nlm.nih.gov/40430518/. doi: 10.3390/ph18050699.

Published

2026-11-18

How to Cite

1.
Nunes da Silva Queiroz Neto W, Aquino da Silva J, de Oliveira Teixeira D, Dos Santos Souza AC, Dell’Acqua Cassão Rezende B. Efficacy of potassium-competitive acid blocker (P-CAB)- based therapeutic regimens in the eradication of resistant Helicobacter pylori strains. Rev Goiana Med [Internet]. 2026 Nov. 18 [cited 2026 Nov. 22];68(72). Available from: https://amg.org.br/osj/index.php/RGM/article/view/750